Hand-Foot and Mucositis Symptom and Impact Questionnaire
For patients experiencing hand-foot syndrome and mucositis/stomatitis as a result of treatment with tyrosine kinase inhibitors
Originally developed as the Supplementary Quality of Life Questionnaire (SQLQ), the HAMSIQ is a valid, reliable, and responsive measure which assesses the impact of hand-foot syndrome and mucositis in patients receiving tyrosine kinase inhibitors.
Hand-Foot and Mucositis Symptom and Impact Questionnaire (HAMSIQ)
NUMBER OF ITEMS:
Patients 18 years and older experiencing hand-foot syndrome and mucositis/stomatitis as a result of treatment with tyrosine kinase inhibitors
Paper and electronic
Self-administration and interview when applicable
TIME FOR COMPLETION:
Available translations of the HAMSIQ can be obtained when licensing the measure. Users are not permitted to translate the HAMSIQ without prior permission from FACIT.org. Permission may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor of the HAMSIQ.
Please contact us for more information.
Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained.
Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use.
To license an available version of this measure for commercial or non-commercial use, please complete our registration form. All of the information provided in the form will be kept strictly confidential. For questions, please contact us.
Lai JS, Beaumont JL, Diaz J, Khan S, Cella D. Validation of a short questionnaire to measure symptoms and functional limitations associated with hand-foot syndrome and mucositis in patients with metastatic renal cell carcinoma. Cancer. 2016 Jan 15;122(2):287-95. doi: 10.1002/cncr.29655. Epub 2015 Oct 12. PMID: 26457466.